Option Care Health, Inc. (NASDAQ:OPCH – Get Rating) was the target of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 5,140,000 shares, a growth of 24.2% from the March 15th total of 4,140,000 shares. Based on an average trading volume of 1,300,000 shares, the short-interest ratio is currently 4.0 days. Currently, 2.9% of the shares of the stock are sold short.
Wall Street Analysts Forecast Growth
Separately, Jefferies Financial Group assumed coverage on Option Care Health in a research report on Monday, February 27th. They set a “buy” rating for the company.
Insider Buying and Selling
In other Option Care Health news, insider Michael Bavaro sold 6,148 shares of the firm’s stock in a transaction on Friday, March 10th. The shares were sold at an average price of $31.45, for a total value of $193,354.60. Following the completion of the transaction, the insider now directly owns 21,549 shares of the company’s stock, valued at approximately $677,716.05. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.22% of the stock is currently owned by insiders.
Institutional Trading of Option Care Health
Hedge funds have recently bought and sold shares of the company. Congress Wealth Management LLC DE raised its stake in shares of Option Care Health by 10.1% during the first quarter. Congress Wealth Management LLC DE now owns 45,468 shares of the company’s stock worth $1,445,000 after acquiring an additional 4,180 shares in the last quarter. Ellsworth Advisors LLC raised its position in Option Care Health by 3.6% in the 1st quarter. Ellsworth Advisors LLC now owns 13,556 shares of the company’s stock worth $431,000 after purchasing an additional 465 shares during the period. Rockefeller Capital Management L.P. raised its position in Option Care Health by 2,303.3% in the 4th quarter. Rockefeller Capital Management L.P. now owns 4,374 shares of the company’s stock worth $130,000 after purchasing an additional 4,192 shares during the period. Voya Investment Management LLC lifted its stake in Option Care Health by 145.7% in the fourth quarter. Voya Investment Management LLC now owns 264,571 shares of the company’s stock worth $7,961,000 after purchasing an additional 156,897 shares during the last quarter. Finally, Macquarie Group Ltd. boosted its position in Option Care Health by 42.0% during the fourth quarter. Macquarie Group Ltd. now owns 952,132 shares of the company’s stock valued at $28,650,000 after buying an additional 281,488 shares during the period. Institutional investors own 97.63% of the company’s stock.
Option Care Health Stock Performance
NASDAQ OPCH opened at $31.69 on Monday. Option Care Health has a 52-week low of $25.53 and a 52-week high of $35.87. The company has a fifty day moving average of $30.85 and a 200-day moving average of $30.57. The company has a market capitalization of $5.70 billion, a P/E ratio of 38.18, a P/E/G ratio of 2.56 and a beta of 1.14. The company has a debt-to-equity ratio of 0.76, a quick ratio of 1.36 and a current ratio of 1.76.
Option Care Health (NASDAQ:OPCH – Get Rating) last issued its quarterly earnings results on Thursday, February 23rd. The company reported $0.26 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.04. Option Care Health had a return on equity of 11.51% and a net margin of 3.82%. The firm had revenue of $1.03 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same quarter in the previous year, the company posted $0.24 earnings per share. The company’s revenue was up 10.8% compared to the same quarter last year. As a group, equities research analysts predict that Option Care Health will post 0.93 EPS for the current fiscal year.
Option Care Health Company Profile
Option Care Health, Inc engages in the provision of home and alternate site infusion services. The firm provides infusion therapy and other ancillary healthcare services through a national network of full-service pharmacies. The company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources to provide pharmaceuticals and complex compounded solutions to patients for intravenous delivery in the patients’ homes or other nonhospital settings.